Cross-sectional quantitative validation of the pediatric Localized Scleroderma Quality of Life Instrument (LoSQI): A disease-specific patient-reported outcome measure.

Christina K ZiglerL LinK ArdalanH JacobeS LaneS C LiN J C LucaV H PrajapatiK SchollaertN TeskeK Torok

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

Results from a representative sample of children and adolescents with LS continue to support the validity of the LoSQI when used in a clinical setting. Future work to evaluate the responsiveness is ongoing.

Keyphrases

patient reported outcomes
cross sectional
systemic sclerosis
current status
high resolution
interstitial lung disease
rheumatoid arthritis
mass spectrometry